| HS Code | 652267 |
| Productname | PURASORB PL 18 |
| Chemicalname | Poly(L-lactide) |
| Abbreviation | PLLA |
| Synonyms | Poly(L-lactic acid); L-PLA |
| Casnumber | 26100-51-6 |
| Molecularformula | (C3H4O2)n |
| Grade | Medical Device |
| Manufacturer | Corbion |
| Appearance | White to off-white granules |
| Form | Granules/pellets |
| Inherentviscosity | 1.8 dL/g (chloroform, 30 °C) |
| Molecularweight | Approximately 200,000-300,000 g/mol |
| Meltingpoint | 170-180 °C |
| Glasstransitiontemperature | 55-65 °C |
| Density | 1.24-1.30 g/cm3 |
| Crystallinity | Semi-crystalline |
| Solubility | Soluble in chloroform, dichloromethane, dioxane; insoluble in water |
| Degradationproducts | Lactic acid |
| Biodegradability | Resorbable/biodegradable |
| Sterilizationcompatibility | Gamma irradiation; ethylene oxide |
| Storageconditions | Cool, dry, protect from moisture and heat |
| Shelflife | 2 years (typical, under recommended storage) |
| Processingmethods | Melt extrusion; injection molding |
| Applications | Medical implants; sutures; drug delivery |
As an accredited PURASORB PL 18 Medical Device Poly(L-lactide) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | PURASORB PL 18, 1 kg, is supplied in a sealed moisture-barrier foil bag with desiccant and medical-device labeling. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for PURASORB PL 18 Medical Device Poly(L-lactide), palletized cargo, securely stowed for ocean shipment. |
| Shipping | Shipping description: PURASORB PL 18 Medical Device Poly(L-lactide) is non-hazardous and not regulated for transport; no UN number or hazard class. Ship ambient in sealed moisture-barrier packaging, unless refrigerated. Protect from heat, moisture, and sunlight. Store cool, dry. Keep containers closed until use. Follow manufacturer’s instructions. No special ventilation required. |
| Storage | Store PURASORB PL 18 Medical Device Poly(L-lactide) in its original, tightly sealed container in a cool, dry, dark place, preferably refrigerated at 2–8 °C. Protect from moisture, heat, oxygen, and direct light. Allow the container to equilibrate to room temperature before opening to prevent condensation. Avoid prolonged exposure to open air and follow supplier shelf-life instructions. |
| Shelf Life | Typically 24 months from date of manufacture when stored unopened under recommended cool, dry conditions, protected from moisture and light. |
Melt-state conversion of PURASORB PL 18 into load-bearing osteosynthesis hardware begins with closed-loop desiccant drying to hold residual moisture below 200 ppm. A moisture level above 300 ppm triggers hydrolytic chain scission during plastication, producing non-uniform melt viscosity and embrittled molded parts. The resin is plastified with a reciprocating screw having an L/D ratio of 20:1 to 24:1 and a compression ratio of 2.5:1 to 3.0:1. Barrel temperatures from feed to nozzle are typically profiled at 170°C, 185°C, 195°C, 200°C, and 195°C. Mold temperature is held between 25°C and 60°C to control quench depth and downstream crystallinity. The stable melt-processing window is no wider than ±5°C around the 195–205°C plateau; excursions above 210°C cause measurable inherent viscosity loss within 10 min of residence time. After molding, annealing at 110°C for 2 h under vacuum or nitrogen raises crystallinity from 5–10% to 35–45%, increasing flexural modulus but reducing elongation at break below 5%. Mechanical test specimens are evaluated under ASTM D638-14 for tensile properties and ASTM F2502-17 for bioabsorbable plate and screw performance. Terminal products include cortical bone screws, craniofacial fixation plates, and osteochondral tacks. Terminal sterilization is preferentially ethylene oxide under ISO 11135:2014; gamma irradiation at 25 kGy may reduce molecular weight and must be validated for each implant geometry before release.
| Downstream route | Primary standards | Characteristic controlled |
|---|---|---|
| Orthopedic injection molding | ASTM F2502-17, ISO 13781:2017, ISO 10993-1:2018 | Strength retention, degradation profile, biological safety |
| Vascular scaffold tubing | ISO 25539-2:2020, ISO 10993-1:2018 | Radial collapse, fatigue, particulate generation |
| Suture anchor | ASTM F1839-08, ISO 13781:2017 | Torque and pull-out in rigid polyurethane foam |
| Microsphere drug delivery | ICH Q3C, USP <788>, ISO 10993-1:2018 | Residual solvent, particulate size, release behavior |
| Barrier membrane | ISO 22803:2004, ISO 11135:2014 | Cell occlusivity, tear resistance, degradation |
| Radiopaque mesh | ASTM F2502-17 adapted, ISO 10993-1:2018 | Flexural modulus, impact resistance, radiopacity |
Bioresorbable vascular scaffold tubing made from PL 18 is produced on a microextrusion line integrating a single-screw extruder with a 24:1 L/D ratio, a barrier screw with compression ratio 3.0:1 to 3.5:1, and a melt pump to damp pressure pulsation. The resin is vacuum-dried at 80°C for 12 h to achieve moisture below 100 ppm. Die melt temperature is controlled between 200°C and 215°C, but total residence time must remain below 10 min because thermal degradation generates lactide monomer and reduces molecular weight preferentially at the die land. Drawdown is limited by low melt strength; draw resonance and diameter oscillation are observed when haul-off speed exceeds a critical ratio that depends on die gap and melt temperature. The extruded tube is cut by femtosecond laser at 1030 nm wavelength to produce strut widths near 150 µm, minimizing heat-affected zone and edge cracks. Post-processing includes radial expansion at a temperature above the glass transition but below the cold crystallization onset, followed by crimping onto a balloon catheter. Bench testing under ISO 25539-2:2020 evaluates radial stiffness, collapse pressure, and pulsatile fatigue. The finished scaffold is a bioresorbable vascular scaffold intended to degrade by bulk hydrolysis over a period of more than 24 months, not a permanent metallic endoprosthesis. Processors must validate molecular weight retention after each extrusion lot because the polymer exhibits a narrow secondary processing window between orientation and thermal relaxation.
Injection-molded PL 18 suture anchors are annealed to develop a rigid core because torque transmission depends on crystalline reinforcement rather than ductile deformation. Annealing at 110–120°C for 2–4 h under nitrogen raises crystallinity from the as-molded range of 10–20% to 40–50%. The increase in crystallinity reduces creep under sustained load but also lowers impact resistance, so the anchor wall thickness is kept above 1.2 mm for threaded designs. Cannulated anchors are molded with core pins from 1.2 mm to 2.0 mm in diameter; pin deflection during injection must be controlled to prevent wall asymmetry exceeding 0.1 mm. Insertion torque is measured in rigid polyurethane foam of density 0.32 g/cm³ according to ASTM F1839-08. Published data for specific configurations show initial insertion torque in the range of 6–12 N·cm, with pull-out strength retention between 50% and 70% after 12 weeks in phosphate-buffered saline at 37°C; design-specific verification remains mandatory because thread geometry and sterilization history alter the degradation response. Terminal products include threaded and knotless suture anchors for rotator cuff and labral repair. The polymer’s high inherent viscosity supports mechanical integrity through the early soft-tissue healing window, but amine-containing suture materials or bone cements should be evaluated for compatibility because free amines can catalyze ester hydrolysis at the anchor interface.
Solvent selection in drug-loaded microspheres determines encapsulation efficiency, particle size distribution, and residual solvent burden. A dichloromethane solution of PL 18 at 5–15 wt% is emulsified into an aqueous continuous phase containing 0.5–2.0 wt% poly(vinyl alcohol). The high molecular weight of PL 18 raises continuous-phase viscosity; at oil-phase concentrations above 15 wt%, the emulsion becomes difficult to atomize and the particle size distribution broadens beyond a span of 1.5. Homogenization at 5000–10000 rpm yields microspheres in the 20–80 µm range at an oil-to-water phase ratio between 1:5 and 1:20. Theoretical drug loading can be set between 5 wt% and 30 wt%, but encapsulation efficiency drops when the polymer-to-drug ratio falls below 4:1. A drug with high aqueous solubility may produce an initial release burst above 25% within 24 h; this must be suppressed by adjusting solvent removal rate and particle hardening. Residual dichloromethane is reduced by vacuum drying at 30–40°C for 24–48 h to below the ICH Q3C Class 2 limit of 600 ppm. Terminal products are injectable poly(L-lactide) microspheres for intra-articular depot or particulate embolization. Sterilization strategy is generally aseptic manufacturing or low-dose ethylene oxide; gamma irradiation of drug-loaded microspheres frequently alters both polymer molecular weight and drug stability, so radiation dose mapping is mandatory if used.
In guided bone regeneration, a solution-cast PL 18 film is dried in a cleanroom environment and oriented to produce a cell-occlusive barrier with a thickness between 50 µm and 200 µm. The resin is dissolved in chloroform or dioxane at 5–10 wt%, cast on a polished borosilicate plate, and dried under controlled solvent pressure to avoid skin-over and pinhole formation. Uniaxial stretching at 60–80°C with a draw ratio of 3:1 to 5:1 improves tear resistance but reduces in-plane ductility, so the film is annealed at 90°C for 1 h to set dimensional stability. Terminal sterilization by ethylene oxide according to ISO 11135:2014 is followed by aeration to remove residual sterilant. Gamma irradiation at 25 kGy is normally excluded unless mechanical performance loss is specifically validated, because oriented PLLA chains undergo chain scission at doses above 10 kGy. The membrane is tested for cell occlusivity and degradation profile under ISO 22803:2004 and biological evaluation under ISO 10993-1:2018. Terminal products include resorbable membranes for socket preservation and alveolar ridge augmentation. Bulk erosion begins after 6–12 months of hydrolysis in aqueous media, and complete resorption may require more than 24 months depending on membrane thickness, crystallinity, and local tissue fluid exchange. Published formulation data for this specific brand grade and membrane configuration are limited; therefore, lot-to-lot molecular weight retention must be verified by inherent viscosity measurement before solvent casting.
Compounding radiopaque PL 18 for orbital floor or craniofacial mesh introduces a rheological penalty that sharply narrows the forming window. Barium sulfate with a median particle size of 0.4–1.0 µm is incorporated at 10–15 wt%; above 15 wt%, zero-shear viscosity approximately doubles and melt strength drops sufficiently to cause sheet rupture during thermoforming. Twin-screw compounding is performed on a 40:1 L/D co-rotating extruder at 180–195°C, with filler fed through a side stuffer at zone 5 to limit agglomerate formation and screw wear. The filled resin is extruded into sheet and thermoformed into mesh with strut widths of 0.3–0.8 mm. A loading of 10 wt% barium sulfate provides radiopacity under standard X-ray imaging; higher loading is usually unnecessary and reduces elongation at break below 3%. Flexural modulus is measured under ISO 178:2019, and impact resistance is assessed on notched specimens under ISO 179-1:2010. Processors must avoid amine-containing colorants, coatings, or cleaning residues because free amines catalyze ester hydrolysis at the filler-polymer interface. The barium sulfate fraction does not resorb and remains as an inert residual marker after polymer mass loss; long-term clinical risk assessment of retained particles is required. Terminal products are radiopaque resorbable meshes and fixation buttons used in craniofacial reconstruction. Sterilization is ethylene oxide under ISO 11135:2014; if radiation sterilization is evaluated, dose mapping must account for filler shielding and accelerated chain scission in the amorphous phase.
Competitive PURASORB PL 18 Medical Device Poly(L-lactide) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618136850665 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618136850665
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
PURASORB PL 18 Medical Device Poly(L-lactide) is a semicrystalline aliphatic polyester synthesized by ring-opening polymerization of L-lactide. It is supplied as a medical-grade homopolymer in pellet form for downstream conversion into absorbable implants and finished medical devices, not as a sterile implant or terminal device. The nominal intrinsic viscosity of this grade is 1.8 dL/g when measured in chloroform at 25 °C and a polymer concentration of 0.1 g/dL using dilute-solution capillary viscometry per ISO 1628-1:2021. As an L-lactide homopolymer, PL 18 can crystallize when annealed above its glass transition, typically at 110–120 °C under nitrogen; this semicrystalline character differentiates it from amorphous copolymers such as PDLLA and PLGA and contributes to longer hydrolytic stability under physiological test conditions. The actual resorption time is not intrinsic to the polymer alone and must be established by device-specific testing according to ISO 13781:2017 or ASTM F1635-16.
In dilute solution, the intrinsic viscosity of PL 18 is used as an indirect measure of molecular weight. At equivalent processing temperature, PL 18 exhibits lower melt viscosity than higher-IV PLLA grades such as PL 24 or PL 32, which reduces filling pressure in thin-wall injection molds but also narrows the molecular weight reserve that remains after melt processing. Melt viscosity measurements for PLLA are preferably performed by capillary rheometry at 180–200 °C and shear rates from 10 s⁻¹ to 10,000 s⁻¹; single-point melt mass-flow rate values per ISO 1133-1:2022 are not recommended as a lot-release criterion for this medical grade because the test conditions do not sufficiently control moisture and degradative chain scission. Molders using PL 18 for small orthopedic components maintain barrel zones between 175 °C and 200 °C, hold the nozzle below 200 °C, and keep screw back pressure below 2 MPa to limit shear heating.
Capillary rheometry data for PLLA within this intrinsic-viscosity range show pronounced shear thinning; apparent viscosity at 100 s⁻¹ can be approximately one order of magnitude higher than at 1,000 s⁻¹ at 190 °C. For thin-wall parts, gate sizing should maintain shear rates below 50,000 s⁻¹ to limit shear heating and molecular weight loss. Single-stage screws with L/D 24:1 to 40:1 and compression ratios from 2.5:1 to 3:1 are used for plastication; the feed zone is kept at 170–180 °C, the compression zone at 180–190 °C, and the metering zone at 190–200 °C. A melt temperature above 220 °C is tolerated only with short residence time because ester pyrolysis and lactide monomer reformation accelerate sharply.
Before melt processing, pelletized PL 18 is dried in a desiccant dryer with a dew point below -40 °C and bed air temperature of 80–100 °C for 4–6 h. The target residual moisture is below 250 ppm. At barrel temperatures above 180 °C, moisture hydrolyzes the ester linkages and reduces molecular weight; a single pass through an extruder with moist feed can reduce intrinsic viscosity by more than 0.3 dL/g and create surface splay on molded parts. A twin-screw extruder with L/D 40:1, modular screw elements, and vacuum venting below -0.08 MPa is commonly used for compounding or reactive extrusion control; screw configurations with compression ratios from 2.5:1 to 3:1 and low-shear mixing zones are selected to avoid excessive torque and thermal degradation. The melt residence time is kept below 5 min, and regrind content is limited to 20 % unless lot-specific data demonstrate equivalent molecular weight and color stability.
Gamma irradiation at a nominal dose of 25 kGy in air produces radical-mediated chain scission in PL 18, reducing molecular weight and broadening molecular weight distribution. The effect is dose-rate and atmosphere dependent; irradiation in vacuum or nitrogen reduces oxidative chain scission but does not eliminate it. Devices sterilized by gamma according to ISO 11137-1 should therefore be processed with initial intrinsic viscosity at the upper end of the release interval and tested after terminal sterilization to ISO 527-2:2012 or ISO 178:2019. Ethylene oxide sterilization imposes less molecular weight loss in dry heat-sensitive polyesters, but residual gas limits and aeration must comply with ISO 10993-7:2008. Steam sterilization is not appropriate for PL 18 because moisture and temperature above the glass transition initiate bulk hydrolysis and distort molded geometry.
Validation of gamma sterilization for PL 18 requires post-sterilization intrinsic viscosity and mechanical testing. Electron beam sterilization at equivalent dose produces a narrower dose distribution in uniform devices but still generates chain scission. Absorbed dose mapping is performed according to ISO 11137-2; the maximum observed dose, not the nominal dose, controls molecular weight loss. Packaging for irradiation should exclude oxygen and, when moisture-sensitive, include desiccant. Irradiation in air increases hydroperoxide formation and subsequent hydrolytic degradation at an accelerated rate; therefore, long-term packaging stability studies should include post-sterilization aging at 40 °C and 75 % RH or equivalent accelerated conditions referenced to real-time data.
Injection molding of thin-wall fracture fixation pins, interference screws, and craniofacial plates from PL 18 uses melt temperatures of 180–200 °C and mold temperatures below 40 °C when an amorphous, transparent preform is desired. The part is then annealed at 110–120 °C for 2–4 h under nitrogen to develop crystallinity, increase modulus, and stabilize dimensions. Mold temperature above the PLLA cold-crystallization onset can be selected for in-mold crystallization, but ejection and handling require longer cooling and controlled tools. Part design avoids sharp wall-thickness transitions because differential crystallization shrinkage generates internal stress and reduces impact load capacity. Tensile and flexural property measurements to ISO 527-2:2012 and ISO 178:2019 are required after annealing because crystallinity, not intrinsic viscosity alone, controls short-term mechanical performance.
Annealing of PL 18 also changes solvent uptake and degradation behavior. Specimens cooled rapidly below the glass transition retain amorphous regions that hydrolyze first, while annealed specimens develop crystalline domains that resist water ingress. The result is a difference in in vitro mass-loss profiles for chemically identical material; therefore, processing history must be fixed before degradation testing or regulatory test article preparation. Differential scanning calorimetry according to ISO 11357-2:2020 and ISO 11357-3:2018 is used to document glass transition, cold crystallization, and melting endotherm before lot acceptance.
PL 18 differs from PURASORB PDLG and PDLLA grades primarily by its L-lactide homopolymer structure and the absence of glycolide or D-lactide units. Glycolide-containing copolymers are amorphous and absorb water more readily; their ester bonds are more exposed to hydrolytic attack, so mass loss and strength loss occur on shorter timescales under the same test protocols. In contrast, PL 18 can crystallize, which restricts water uptake and chain mobility in the crystalline domains. Degradation of semicrystalline PLLA is therefore heterogeneous: amorphous regions hydrolyze first, while crystalline domains persist and release acidic oligomers more slowly. This difference means PL 18 is selected when a device must retain mechanical integrity for periods longer than amorphous PLGA or PDLLA devices at the same implant site. Direct product comparison requires identical test specimens, pH, temperature, enzyme load, and dynamic loading history; ASTM F1635-16 provides an in vitro degradation method but does not predict clinical behavior.
Relative to higher-IV PLLA homopolymers, PL 18 has a lower molecular weight reservoir. The processing advantage is lower melt viscosity and easier filling of micro-scale features; the trade-off is that hydrolytic chain scission reaches a critical molecular weight for loss of tensile strength earlier if all other factors remain constant. Strength retention comparisons among PLLA grades therefore require molded specimens of equal crystallinity, sterilized by the same method, and conditioned according to ISO 291:2008 at 23 °C and 50 % RH before testing.
In vitro degradation studies on PL 18 are typically conducted in phosphate-buffered saline at 37 °C and pH 7.4 per ASTM F1635-16 or ISO 13781:2017. Specimen geometry, pH refresh rate, and load condition must be controlled because oligomer accumulation autocatalyzes hydrolysis. During early stages, molecular weight loss occurs before mass loss; mechanical strength loss follows as chain scission reduces tie-chain density in the amorphous phase. The crystalline phase persists longer and can maintain mass until the surrounding solution becomes sufficiently acidic. Published data for the specific device geometry of PL 18 may be limited; therefore, implant manufacturers generate degradation curves for each wall thickness, sterilization dose, and annealing history.
A certificate of analysis for lot release of PL 18 typically reports intrinsic viscosity, appearance, and residual monomer or solvent content; the specific release interval is defined by the manufacturer, and users verify that the lot values remain inside their validated process window. The polymer is manufactured under a quality management system conforming to ISO 13485:2016. Biocompatibility of the finished device is evaluated according to ISO 10993-1:2018; chemical characterization per ISO 10993-18:2020 is required when changes in processing or packaging are made. Material-level screening to USP <88> Class VI is commonly reported but is not a substitute for device-level biological evaluation under ISO 10993. Storage of PL 18 should be in closed, dry containers at low temperature; condensation is avoided when opening chilled packaging. Lot-to-lot variation in molecular weight and residual moisture is tracked using ISO 1628-1:2021 and Karl Fischer titration, respectively.
| Standard or test | Boundary |
|---|---|
| ISO 1628-1:2021 | Dilute-solution viscosity for molecular weight tracking; 1.8 dL/g nominal IV in chloroform at 25 °C |
| ISO 13485:2016 | Quality management system for lot manufacture and change control |
| ISO 10993-1:2018 | Biological evaluation of the finished device; polymer alone does not establish implant safety |
| ISO 10993-18:2020 | Chemical characterization of leachables and processing residuals |
| ISO 11137-1 | Radiation sterilization dose setting and process validation for terminal sterilization |
| ISO 13781:2017 | Requirements for implantable PLLA resins and fabricated forms |
| ASTM F1635-16 | In vitro hydrolytic degradation testing of absorbable polymers and devices |